CAR-T To N-of-1 Studies: How Jeeva Is Helping Drive Trial Efficiencies

Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for numerous point solutions and vendors, enabling sponsors to undertake trials more effectively including in the complex and competitive oncology space.

Jeeva's solutions aim to make trials more efficient • Source: Shutterstock

As biopharma sponsors take on increasingly complex clinical trials, especially in oncology, and regulatory requirements add new expectations around improving participant diversity, innovations big and small that can shake things up or just improve efficiencies will be pivotal. 

The US-based Jeeva Clinical Trials Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from R&D